SIREN : 915390330
PHARMALAM is a French company founded 3 years ago, specialized in the sector Gestion de fonds. Based in BORDEAUX (33200), this company of category PME shows in 2024 a net income positive of 45 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 |
|---|---|---|
| Revenue | N/C | N/C |
| Net income | 44 570 € | 922 786 € |
| EBITDA | -40 510 € | -157 363 € |
| Net margin | N/C | N/C |
In 2024, PHARMALAM generates positive net income of 45 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2023-2024: 923 k€ -> 45 k€.
-40 510 €
-47 242 €
44 570 €
The debt ratio (= Financial debt / Equity x 100) stands at 55%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 64%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 30.8 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.
55.225%
63.966%
30.765
68.6%
In 2024, the debt ratio of PHARMALAM (55.23) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PHARMALAM (64.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of PHARMALAM (30.77) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 11864.54. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
11864.541
-129.161
In 2024, the liquidity ratio of PHARMALAM (11864.54) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of PHARMALAM (-129.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 62 transactions of similar company sales
in 2024,
the value of PHARMALAM is estimated at
329 428 €
(range 93 533€ - 652 632€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 62 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMALAM with other companies in the same sector:
The revenue of PHARMALAM is not publicly disclosed (confidential accounts filed with INPI).
Yes, PHARMALAM generated a net profit of 45 k€ in 2024.
The headquarters of PHARMALAM is located in BORDEAUX (33200), in the department Gironde.
The tax return of PHARMALAM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMALAM operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.